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Background. Erythrocyte sedimentation rate (ESR) is a valuable laboratory tool in evaluation of infectious, inflammatory, and
malignant diseases. Red blood cells in outside from the body precipitate due to their higher density than the plasma. In this study
we discuss the IVIG effect on ESR in different diseases and different ages.Methods and Materials. Fifty patients under 12 years old
who had indication to receive IVIG enrolled in this study. Total dose of IVIGwas 2 gr/kg (400mg/kg in five days or 2 gr/kg in single
dose). ESR before infusion of IVIG and within 24 hours after administration of the last dose of IVIG was checked. Results. 23 (46%)
patients were males and 27 (54%) were females.Themean of ESR before IVIGwas 31.8±29.04 and after IVIG it was 47.2±36.9; this
difference was meaningful (𝑃 = 0.05). Results of ESR changes in different age groups, 6 patients less than 28 days, 13 patients from
1 month to 1 year, 20 patients from 1 to 6 years old, and 11 patients from 6 to 12 years have been meaningful (𝑃 = 0.001, 𝑃 = 0.025,
and 𝑃 = 0.006, resp.). Conclusion. In patients who are receiving IVIG as a therapy, ESR increased falsely (noninflammatory rising);
therefore use of ESR for monitoring of response to treatment may be unreliable. Although these results do not apply to neonatal
group, we suggest that, in patients who received IVIG, interpretation of ESR should be used cautiously on followup.
1. Introduction
The erythrocyte sedimentation rate (ESR) is an acute phase
reactant (APR). The rate of sedimentation in a period of
one hour called ESR and also Biernacki test. ESR test is a
common hematologic nonspecific indicator of inflammation.
To perform a test, nonclothing blood is placed in a vertical
tube (Westergren) and erythrocyte sedimentation rate is
measured and is reported in units of mm/h [1].
The best way to test was presented in 1921 by Westergren,
and it is still the golden standard method for measuring
erythrocyte sedimentation rate. This method is considered
to be [2] simple and cheap, accessible, and accurate [3].
ESR is a valuable laboratory tool in evaluation of infectious,
inflammatory, and malignant diseases [1, 3]. Red blood cells
in outside from the body precipitate due to their higher
density than the plasma; in normal state these cells reject each
other because of their negative surface charges and prevent
Rolex formation. In order to overcome the negative charge of
the red cells should be much stronger gravity. It is exerted by
different types of plasma proteins [4].
It was shown that several factors such as PH levels of
plasma other than the size of molecules or Rolex forma-
tion contribute to erythrocyte sedimentation [2]. ESR levels
increase with age and are higher in women [1, 4, 5], anemia,
and the black people. Clinical factors that do not influence
the ESR are [1, 4] obesity, body temperature, recent food, and
NSAID [1, 4, 5].
IVIG with the half-life of 3-4 weeks was first produced
in 1960 [6, 7]; IVIG in high doses is used for the treat-
ment of many autoimmune diseases including autoimmune
thrombocytopenia, chronic inflammatory polyneuropathy,
Kawasaki disease, and Guillain-Barre´ syndrome [7–9].
High-dose IVIG effects on various proteins, including
inflammatory profiles in 63 children with Kawasaki disease,
were studied. All children had clinical manifestations of
Kawasaki and received 2 gr/kg IVIG and aspirin during 12 hr.
serial testing was carried out before receiving IVIG, 24 hours
and 7 days later.
After IVIG infusion, total WBC and neutrophils were
decreased, whereas lymphocytes were increased. Mean ESR
was 12.7±6.46mm/h before receiving IVIG, 53.3±11.9mm/h
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Table 1: Patients profile.
Patient Disease Age Sex ESR before IVIG ESR after IVIG
1 Icter 4 days M 9 32
2 Icter 2 days F 7 10
3 Icter 2 days F 72 61
4 Icter 2 days M 2 95
5 Icter 10 days M 24 28
6 Icter 4 days M 2 2
7 ITP 35 days F 5 12
8 ITP 2 months M 42 75
9 Sepsis 50 days M 6 15
10 ITP 2 months and 5 days F 47 117
11 ITP 2 months M 16 56
12 ITP 4 months and 19 days M 5 8
13 ITP 17 months M 5 95
14 Sepsis 7.5 months F 52 65
15 Fever resistant 8 months F 17 89
16 Kawasaki 10 months M 54 97
17 Kawasaki 1 year M 90 112
18 ITP 1 year F 65 91
19 ITP 1 year F 12 17
20 GBS 14 months F 89 120
21 Pneumonia + brain tumor 15 months F 137 105
22 GBS 1.5 year M 18 23
23 ITP 1.5 year M 45 72
24 ITP 2.5 years F 10 27
25 Epilepsy resistant 2.5 years M 2 7
26 Epilepsy resistant 2.5 years M 4 4
27 Bulbar palsy + cyanosis 2 years and 6 months M 21 71
28 Epilepsy resistant 2 years and 11 months F 2 5
29 ITP 3 years F 14 28
30 ITP 3 years F 6 17
31 Kawasaki 3 years and 4 months M 115 85
32 Aplastic anemia + fever 4 years F 77 77
33 GBS 4 years M 33 62
34 Encephalitis 4 years and 6 months F 16 33
35 ADEM + fever 5 years F 3 22
36 Brain atrophy + epilepsy 5 years and 4 months M 4 18
37 Encephalitis 5 years and 7 months M 33 33
38 SLE + thrombocytopenia 6 years F 24 44
39 Steven Johnson 6 years M 8 13
40 ITP 7 years F 18 31
41 GBS 7 years M 43 64
42 Vasculitis 7 years F 48 79
43 ITP 8 years F 20 27
44 ITP 8 years F 23 32
45 Bruton 10 years M 2 4
46 Bruton 10 years M 3 2
47 ITP 11 years and 4 months M 10 15
48 ITP 11 years and 7 months F 7 21
49 Dawn + pancytopenia 12 years M 75 121
50 ITP 12 years and 7 months M 10 23
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Table 2: Mean and median of ESR.
Patients Mean ESR SD 𝑃 Median
Before After Before After Before After
50 31.8 47.2 29.04 36.9 0.05 16.5 32
Table 3: Different ages variation.
Age Number Before IVIG After IVIG 𝑃 value
0-1month 6 27.03 ± 19.33 38 ± 34.6 𝑃 = 0.28
1month–1 year 13 32 ± 27.9 65.3 ± 39.9 𝑃 = 0.001
1 year–6 years 20 39.8 ± 33 43.3 ± 34.5 𝑃 = 0.025
6 years–12 years 11 23.5 ± 22.7 38 ± 35.9 𝑃 = 0.006
in 24 h, and 48.8 ± 15.2mm/h in the 7 days after the IVIG
infusion. Protein levels which are associated with systemic
inflammation except ESR decreased after 24 hours.
IgA and IgM immunoglobulin levels did not change 24
hours and 7 days after injection; however, IgG is significantly
increased. The result is that the high dose of IVIG leads to
rapid decreased changes of various proteins except for IgA
and IgM and ESR [10].
In the same study on patients with myasthenia gravis and
Guillain-Barre´ syndrome, similar results were obtained [11].
In this study we discuss the IVIG effect on ESR in different
diseases and ages.We try to answer this question too, is ESR a
valuable APRmarker in evaluation of inflammatory response
to treatment when IVIG is used previously?
2. Method and Materials
This is an analytical descriptive and cross-sectional study.
Fifty patients who had indication to receive IVIG enrolled
in this study. Total dose of IVIGwas 2 gr/kg (400mg/kg in five
days or 2 gr/kg in single dose). ESR before infusion of IVIG
and within 24 hours after administration of the last dose of
IVIG was checked (1-2 gr/kg/12 h or 400mg/kg dose IVIG).
Brand name for the IVIG was OCTAPHARMA AG, Lachen,
Switzerland.
The erythrocyte sedimentation rate was measured by
Westergren method; IVIG side effects were not observed in
any patient. Results have been shown in different age groups,
neonatal, infancy, childhood, and school age.
SPSS 16 and paired 𝑡-test were used to statistical software
analysis; significance level of less than 0.05 was considered
meaningful. Consent confirmed was obtained from parents
of patients.
3. Results
23 (46%) patients were males and 27 (54%) were females
(Table 1). The mean and median ESR before and after
receiving IVIG have been shown in Table 2.Themean of ESR
before IVIG was 31.8 ± 29.04 and after IVIG was 47.2 ± 36.9;
this difference was meaningful (𝑃 = 0.05). In male group the
mean ESR before IVIG was 34.6 ± 33.5 and after IVIG was
49.1 ± 36.2; the difference with (𝑃 = 0.003) is statistically
significant. Before receiving IVIG the mean ESR was 29.4 ±
25.2 in females and after receiving IVIG it was 45.6 ± 38.04;
this difference with (𝑃 = 0.001) is significant. Results of
different age groups, 6 patients less than 28 days, 13 patients
from 1 month to 1 year, 20 patients from 1 to 6 years old, and
11 patients from 6 to 12 years, have been shown in Table 3.
4. Discussion
ESR is known as an important factor in the evaluation of
infectious and inflammatory processes. [2, 4]. Important
point for the use of the ESR as an APR is its role in the
evaluation of response to treatment; decreasing levels of ESR
are considered as a marker of response to therapy.
Plasma fibrinogen and globulins are the major factors
affecting ESR [1, 2]. Fibrinogen is the strongest aggregator [2].
And its concentration in the blood is directly related to the
rate of ESR [1]. Alpha and gamma globulin provide half the
ability of fibrinogen and albumin has the lowest ability in the
sediment of red cells.
However, as mentioned, IVIG as an intravenous immune
globulin is used in many diseases [6, 7]. Whether the admin-
istration of IVIG, influences the ESR value in monitoring of
the response to therapy?
In review of the literature generally two studies were
found about the effect of IVIG on ESR. One of them has
been done on Kawasaki patients and has discussed numerous
parameters of protein and also ESR affected by IVIG [10]
and the subsequent study has been limited to patients with
myasthenia gravis and Guillain-Barre´ syndrome showing
numerous parameters and blood ESR affected by IVIG [11],
but this study has discussed 16 different diseases following
the administration of IVIG and has focused on the changes
in ESR.
IVIG as an immunoglobulin, mostly IgG [7], has aggre-
gator effect on red cells and prevents their negative discharge
forces [2]. Although IVIG has many anti-inflammatory
effects [7] and it is expected to reduce ESR rate, in vivo its
biologic effect is more effective than the immunemodulation
effect.
Themean ESRwas 31.8±29.04 before receiving IVIG and
after IVIG it was 47.2 ± 36.9, with significant differences (𝑃 ≤
0.05).
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These changes were statistically significant in both sexes;
it could be interpreted because of lack of physiologic differ-
ence in children.
In different age groups except the neonatal period, 1
month to 1 year (13 patients), 1 to 6 years (20 patients), 6
to 12 years (11 patients), the mean ESR before IVIG and
after receiving IVIG increased with significant differences; 𝑃
values were, respectively, 𝑃 = 0.001, 𝑃 = 0.025, and 𝑃 =
0.006.
Rapid physiological changes in various neonatal plasma
proteins such as albumin and fibrinogen are the variables
leading to these results [12]. Different immune regulatory
functions of IVIG through its interaction with innate and
adaptive immune system and immune homeostasis in neona-
tal period could be another reason [13].
Among the APR, the ESR is the most valuable criteria for
evaluating and monitoring of response to inflammation [1];
on the basis of this study on patients who are receiving IVIG
as a therapy, ESR increased falsely (noninflammatory rising);
therefore use of ESR for monitoring of response to treatment
may not be reliable.
Based on the knowledge of authors and review of the
literature this study seems to be the only work about ESR
and IVIG administration effect in children. Although these
results do not apply to neonatal group we suggest that, in
patients who receive IVIG, interpretation of ESR should be
used cautiously on the followup process.
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